TLC BioSciences Reports Positive TLC590 Phase 3 Topline Results
TLC BioSciences says its pivotal Phase 3 trial of investigational TLC590 showed statistically significant reductions in pain and opioid use versus placebo and liposomal bupivacaine.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.